Unibest

Pharmaceutical intermediates

Ubrogepant Intermediates

4 pharmaceutical intermediates for Ubrogepant. Indication: Migraine Disorders.

提交项目All intermediates

About Ubrogepant

Originator
Abbvie
Indication
Migraine Disorders
Approved Date
12/23/2019
DS/DP
11/10/2031

Available intermediates

4 intermediates currently listed for Ubrogepant. Request specifications, documentation or a quotation for any item below.

Ubrogepant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(S)-1'-(tert-butyl)-3-chloro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one1455358-14-1//
1-(tert-butyl)-3-((5-chloro-3-(hydroxymethyl)pyridin-2-yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one1455358-11-8//
Ubrogepant Intermediate1375541-21-1//
(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidine-3-aminium 4-nitrobenzoate1456803-37-4//

Other programs under U

UmbralisibUpadacitinib

Building toward Ubrogepant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →